News

News

November 5, 2019
DBV Technologies to Present at the Stifel 2019 Healthcare Conference
October 24, 2019
DBV Technologies to Highlight the Burden of Peanut Allergy and Patient Experiences with Viaskin Peanut at ACAAI 2019
October 15, 2019
DBV Technologies Announces Closing of Global Offering
October 10, 2019
DBV Technologies Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares (ADSs)
October 9, 2019
DBV Technologies Announces Pricing of $125 million (€114 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares
October 8, 2019
DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports September 30, 2019 Cash Position
October 4, 2019
DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut for the Treatment of Peanut Allergy
August 7, 2019
DBV Technologies Submits Biologics License Application to U.S. Food and Drug Administration for Viaskin Peanut for the Treatment of Peanut Allergy
August 1, 2019
DBV Technologies Reports First Half 2019 Financial Results
July 18, 2019
Amendment to the DBV Technologies Liquidity Contract with NATIXIS ODDO BHF and Half-Year Report
Investor Relations Contact
Jonathan Neely

jonathan.neely@dbv-technologies.com

Media Contact
Brett Whelan
brett.whelan@dbv-technologies.com
Subscribe to get the latest DBV press releases
Subscribe
Scroll to Top